“Companies with Key Catalysts Over the Next 12-18 Months” was moderated by Prakhar Agrawal. It featured Lars Pirgerson, President of Adlai Nortye Ltd., Gail McIntyre, CEO of Aravive, Inc., and Debanjan Ray, CEO of Synthekine.

• Synthekine is developing a differentiated pipeline of specific, selective, and potent cytokine therapeutics against a wide range of high-value targets. It noted its most advanced clinical product, STK-012, a modified IL-2 cytokine is drastically different than most IL-2 approaches as STK-012 is an α/ß-biased IL-2 partial agonist and preferentially stimulates only tumor killing T cells. STK-012 is in a phase 1 trial in solid tumors as monotherapy and combination with initial clinical data expected next year. Synthekine also noted its orthogonal IL-2 cytokine cell therapy platform that the company believes could drive deeper and more durable responses with reduced toxicities across various cell therapy modalities.

• Aravive highlighted the opportunity for batiraxcept, high affinity, highly specific GAS6/ADX inhibitor, in platinum resistant ovarian cancer with topline data from phase 3 trial expected middle of 2023. It also noted the potential for batiraxcept in clear cell renal cancer and pancreatic adenocarcinoma.

• Adlai Nortye is focused on the discovery and development of innovative cancer therapies for patients across tumor types, with multi-national R&D centers in both China and the United States. It highlighted its most advanced drug, buparlisib, is a pan-PI3K inhibitor that is in a registrational trial in metastatic Head and Neck Squamous Cell Carcinoma. The company also highlighted the potential of its other pipeline drugs, palupiprant and AN4005, in solid tumors.

#Cantorconferenceseries #Oncology #Hematology #Hemeonc #Cantorfitzgerald #Cantorhealthcare